Cargando…

Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma

PURPOSE: Thyroid dysfunction is the most common immune-related adverse event during anti-programmed cell death 1 (anti-PD-1) therapy. In this study, we monitored patients with advanced malignant tumors who received anti-PD-1 therapy to observe the characteristic of anti-PD-1 therapy-induced thyroid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yiran, Li, Qingchen, Xu, Lusi, Zheng, Yanqing, Wang, Yanchao, Liu, Ying, Zhang, Rui, Liao, Lin, Dong, Jianjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645623/ https://www.ncbi.nlm.nih.gov/pubmed/37715029 http://dx.doi.org/10.1007/s00432-023-05364-z

Ejemplares similares

Thyroid dysfunction during PD-1 inhibitor treatment in patients with cancer: Incidence and association with progression-free survival
por: Wu, Yanfei, et al.
Publicado: (2022)

Estimating disease-free survival of thyroid cancer based on novel cuprotosis-related gene model
por: Du, Rui, et al.
Publicado: (2023)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

The clinical characteristics and gene mutations associated with thyroid hormone resistance syndrome coexisting with pituitary tumors
por: Zhao, Junyu, et al.
Publicado: (2023)

Plasma D‐dimer and interleukin‐6 are associated with treatment response and progression‐free survival in advanced NSCLC patients on anti‐PD‐1 therapy
por: Chen, Chong, et al.
Publicado: (2023)

Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis
por: Zhou, Zhirui, et al.
Publicado: (2021)

Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial
por: Zheng, Yanqing, et al.
Publicado: (2021)

A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy
por: Lin, Jingwei, et al.
Publicado: (2023)

Locoregional progression-free survival of bone metastases from differentiated thyroid cancer
por: Luo, Jiaxin, et al.
Publicado: (2022)

Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response
por: Chen, Zi-Hang, et al.
Publicado: (2023)

DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
por: Niebel, Dennis, et al.
Publicado: (2022)

The relationships between thyroid functions of short-term rapid hypothyroidism and blood lipid levels in post-thyroidectomy patients of differentiated thyroid cancer
por: Yao, Jinming, et al.
Publicado: (2023)

Anaplastic Thyroid Cancer Presenting With Brain Metastasis: 17-year Progression Free Survival
por: Howard, Kathryn Kay, et al.
Publicado: (2021)

Protective effect of Cordyceps sinensis against diabetic kidney disease through promoting proliferation and inhibiting apoptosis of renal proximal tubular cells
por: Zhang, Yuhan, et al.
Publicado: (2023)

Liver dysfunction and anti-thyroid therapy
por: Papachristos, Danae A, et al.
Publicado: (2015)

Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
por: Wu, Tiantian, et al.
Publicado: (2023)

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer
por: Grevel, Joachim, et al.
Publicado: (2019)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
por: Dora, David, et al.
Publicado: (2023)

Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis
por: Ye, Jiabu, et al.
Publicado: (2020)

Chronic Exercise Protects against the Progression of Renal Cyst Growth and Dysfunction in Rats with Polycystic Kidney Disease
por: QIU, JIAHE, et al.
Publicado: (2021)

Neurology: A Better Model for PD
por: Heimer, Hakon
Publicado: (2004)

ATP protects anti-PD-1/radiation-induced cardiac dysfunction by inhibiting anti-PD-1 exacerbated cardiomyocyte apoptosis, and improving autophagic flux
por: Wang, Jing, et al.
Publicado: (2023)

MON-446 Anaplastic Thyroid Cancer Presenting with Brain Metastasis: 17-Year Progression Free Survival
por: Howard, Kathryn Kay, et al.
Publicado: (2020)

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
por: Gunda, Viswanath, et al.
Publicado: (2018)

C-reactive protein and thyroid-stimulating hormone levels as risk factors for hypothyroidism in patients with subacute thyroiditis
por: Tang, Chenjia, et al.
Publicado: (2021)

Multi-Parameter MR Radiomics Based Model to Predict 5-Year Progression-Free Survival in Endometrial Cancer
por: Liu, Defeng, et al.
Publicado: (2022)

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
por: Iivanainen, Sanna, et al.
Publicado: (2019)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
por: Mehnert, Janice M., et al.
Publicado: (2019)

Risk Factors for Thyroid Dysfunction in Patients with Advanced Non-Small-Cell Lung Cancer Treated with PD-1 Antibody
por: Zhang, Junjun, et al.
Publicado: (2022)

SAT-LB75 Thyroid Peroxidase Antibody Positivity Predicts Relapse Free Survival Following Anti-Thyroid Drug Treatment for Graves Disease
por: Muir, Christopher Alan, et al.
Publicado: (2020)

Editorial: Recent advances in papillary thyroid carcinoma: Progression, treatment and survival predictors
por: Volpi, Erivelto Martinho, et al.
Publicado: (2023)

Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma
por: Pu, Haihong, et al.
Publicado: (2015)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

CT-Based Radiomics Nomogram for Prediction of Progression-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yan, Chang, et al.
Publicado: (2021)

Furin Overexpression Suppresses Tumor Growth and Predicts a Better Postoperative Disease-Free Survival in Hepatocellular Carcinoma
por: Huang, Ya-Hui, et al.
Publicado: (2012)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

Retracted: Risk Factors for Thyroid Dysfunction in Patients with Advanced Non-Small-Cell Lung Cancer Treated with PD-1 Antibody
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Development and validation of a nomogram based on stromal score to predict progression‐free survival of patients with papillary thyroid carcinoma
por: Tang, Jiajia, et al.
Publicado: (2021)

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
por: Djureinovic, Dijana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f4nh28kk1slbrsgoh591p25r4v